A study of interferon beta/ ribavirin plus non-activated vitamin D combination therapy for chronic hepatitis C and decompensated cirrhosis patients.

A study of interferon beta/ ribavirin plus non-activated vitamin D combination therapy for chronic hepatitis C and decompensated cirrhosis patients. - Interferon beta with/without ribavirin plus non-activated vitamin D combination therapy for chronic hepatitis C and decompensated cirrhosis patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010812

Enrollment

Registered

2013-05-27

Start date

2013-05-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C patients and compensated cirrhosis patients

Interventions

Chronic hepatitis C with high viral load: Vitamin D(2000IU/day)for 4 weeks, vitamin D, IFN-beta(6 MIU)and ribavirin(600-1000mg/day)for 48 weeks. Negative result of HCV RNA test at 12-36 weeks for 72

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic hepatitis C and compensated cirrhosis patients with serogroup 1 and low viral load, with serogroup 2.

Exclusion criteria

Exclusion criteria: pregnant women and nursing mothers

Design outcomes

Primary

Measure	Time frame
Negative result of HCV RNA test at 24 weeks after therapy.	—

Countries

Japan

Contacts

Public ContactNobuaki Nakayama

Saitama Medical University Division of Gastroenterology and Hepatology ,internal Medicine

hirb@saitama-med.ac.jp049-276-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026